Study of fb1001 for recent optic nerve damage
Part of Brain & nervous system, Eyes & vision clinical trials.
This early-stage study tests an investigational drug called FB1001 for people who have recently experienced a type of sudden vision loss from either acute angle-closure glaucoma or a stroke-like event in the optic nerve (NAION). The treatment aims to protect the optic nerve and potentially preserve your remaining vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 40 years old.
- You must have one of two conditions: acute primary angle-closure glaucoma with optic nerve damage (recent attack, high eye pressure) OR non-arteritic anterior ischemic optic neuropathy (recent vision loss from reduced blood flow to the optic nerve).
- Your vision in the affected eye must be good enough to read letters on an eye chart (better than 20/40 for glaucoma, or at least 15 letters for NAION).
- Your eye pressure must be under 21 mmHg (controlled) before the study starts.
- You cannot have severe other eye diseases, recent eye surgery, or certain health conditions (like heart disease, autoimmune disease, or cancer) that might interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to look at inflammation in blood vessels around the eye in two conditions: giant cell arteritis (GCA, a type of blood vessel inflammation) and ischemic optic neuropathy (a condition where the optic nerve doesn't get enough blood). The goal is to better understand how inflammation affects the optic nerve and vision, which could help guide future treatments.
This study tests if a gentle electrical current, like a light flicker, can help people with optic neuropathy (damage to the nerve connecting the eye to the brain). You would attend 30 sessions over 8 weeks. It might improve your vision if you still have some sight left.
This trial tests whether a new drug, ER-100, is safe for people with glaucoma or a sudden optic nerve injury called NAION. It aims to see if the drug can be given without serious side effects.
This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.
This study tests new, non-invasive ways to measure how the retina (the light-sensing part of the eye) is structured and how well it works. It may help researchers better understand certain vision disorders and how to track them, without surgery or injections.
This study looks at how blood flows in the optic nerve (the nerve that carries visual information from the eye to the brain) using advanced imaging. It aims to better understand different optic nerve conditions, which may help improve diagnosis and treatment in the future.
Hear when a new Optic Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.